Get instant alerts when news breaks on your stocks. Claim your one week free trial for StreetInsider Premium here.
PIOMBINO DESE, Italy–(BUSINESS WIRE)–Stevanato Group SpA (NYSE: STVN), a leading global provider of containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and science industries of Life, announced today that it will participate in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum. Management will present virtually at 9:00 a.m. EDT on Tuesday, March 22, 2022.
A live audio webcast will be available on the Company’s website at www.stevanatogroup.com under the “Investors” section of the site. A replay will be available for approximately 90 days after the event.
This press release may contain certain forward-looking statements that include, or may include, words such as “will”, “believe”, “future”, “expect”, “foreseeable”, “planned”, “be”. , “estimated”, “assumes”, “would provide” and other similar expressions (or their negative). Forward-looking statements in this press release include, but are not limited to, statements regarding our participation in the KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
The forward-looking statements contained in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. These forward-looking statements speak only as of their dates. Stevanato Group undertakes no obligation to update any statement or forward-looking statement to reflect events or circumstances after the date on which such statement is made or to reflect the occurrence of unforeseen events. New factors appear from time to time, and it is not possible to predict all of these factors. Further, Stevanato Group cannot assess the impact of each of these factors on our business or the extent to which any one factor, or combination of factors, could cause actual results to differ materially from those contained in the forward-looking statements. Readers should therefore not place undue reliance on such statements, particularly in connection with any contract or investment decision.
About the Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of containment, drug delivery and diagnostic solutions for the pharmaceutical, biotechnology and life science industries. The Group offers an integrated end-to-end portfolio of products, processes and services that meet customer needs throughout the life cycle of medicines at each of the development, clinical and commercial stages. The Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and engineering excellence are central to its ability to deliver value-added solutions to its customers.
For more information, please visit www.stevanatogroup.com
Source: Stevanato SpA Group